MedTrace Logo

Endothelial Damage and Angiogenesis Biomarkers During COVID-19

NCT04609332 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2023-07-25

No results posted yet for this study

Summary

Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis.

This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.

Conditions

  • Covid19
  • Angiogenesis
  • Endothelial Dysfunction
  • Cardiovascular Morbidity

Interventions

DIAGNOSTIC_TEST

Endothelial damage and angiogenic biomarkers

Blood samples for biomarkers study

Sponsors & Collaborators

  • University of Chile

    lead OTHER

Principal Investigators

  • Felipe Maldonado, M.D., M.Sc. · Hospital Clínico de la Universidad de Chile

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-10
Primary Completion
2021-09-26
Completion
2021-11-30

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04609332 on ClinicalTrials.gov